Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 8/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23650062 | 0.91 | TYMP (0.58) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL30091055 | 0.91 | TYMP (0.58) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL7708120 | 0.91 | TYMP (0.58) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL30396368 | 0.91 | TYMP (0.58) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL6513309 | 0.91 | TYMP (0.58) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL31676703 | 0.88 | TYMP (0.60) | TYMPADORA1MEN1KMT2A | |
| SCHEMBL17417837 | 0.88 | TYMP (0.48) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL6899475 | 0.87 | TYMP (0.56) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL6898807 | 0.86 | TYMP (0.55) | TYMPADORA1P2RY12ADORA2AADORA2B | |
| SCHEMBL6900160 | 0.86 | TYMP (0.56) | TYMPADORA1P2RY12ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067964-B2 | Complex and method for enhancing nuclear delivery | OLIGOMER SCIENCES AB (SE) | 2015-06-30 | — | — | US | disclosed |
| US-20110306138-A1 | COMPLEX AND METHOD FOR ENHANCING NUCLEAR DELIVERY | OLIGOMER SCIENCES AB (SE) | 2011-12-15 | — | — | US | disclosed |
| EP-2376518-A1 | A COMPLEX AND METHOD FOR ENHANCING NUCLEAR DELIVERY | Avaris AB (SE) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071587-A1 | A COMPLEX AND METHOD FOR ENHANCING NUCLEAR DELIVERY | AVARIS AB (SE) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306138-A1 | COMPLEX AND METHOD FOR ENHANCING NUCLEAR DELIVERY | SNRPE, SNRPA, HNRNPH3 | TYMP 379/4885ADORA1 2916/4885P2RY12 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.